Quick Takeaways
- Viromed Medical entered a global distribution partnership with NEBU-TEC to combine its cold plasma technology platform PulmoPlas with NEBU-TEC’s inhalation and nebulization systems for veterinary and future human respiratory applications
- Under the agreement, NEBU-TEC received worldwide exclusive distribution rights for veterinary applications of PulmoPlas. The initial focus will be the treatment of pulmonary diseases in horses through PulmoPlas vet, targeting the growing European equine respiratory care market, with launch planned later in 2026
- Viromed Medical stated that the collaboration strengthens the international commercialization strategy for its cold plasma technology platform while also creating a pathway for future human applications using NEBU-TEC’s EU MDR Class IIa-certified inhalation devices
Why It Matters?
This deal gives Viromed a faster route to commercialize PulmoPlas in veterinary respiratory care, starting with horses, while NEBU-TEC gets exclusive global distribution rights in that segment. The biggest market upside is in Europe’s equine respiratory market, where a 2026 launch could help PulmoPlas become an add‑on option for airway disease management.
More broadly, the partnership helps validate PulmoPlas as a platform and could create a bridge into human respiratory use later, because it is being paired with NEBU-TEC’s EU MDR Class IIa inhalation devices. That makes the collaboration more than a veterinary licensing deal, it is also a strategic step toward building a broader respiratory commercialization pipeline.
Source: Newsmediawire
